Latest news

• AZ divests European rights for cholesterol med Crestor to Grünenthal

  This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients,” said Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit,

• AstraZeneca divests Seroquel rights to focus on key therapy areas

  This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas,” said Ruud Dobber, executive vice president, BioPharmaceutical Business Unit at AZ.

• AZ’s Farxiga gets heart failure prevention okay from FDA

  attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ.

• AstraZeneca sells Losec rights as part of refocus strategy

  with high unmet medical need,” said Ruud Dobber, executive vice president of BioPharmaceuticals at AZ.

• AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

  Dave Fredrickson retains his position as head of the global oncology business unit, and Ruud Dobber – formerly AZ’s head of North American commercial operations – will take over the running of